Combindation treatment with Grazoprevir and Elbasvir fixed dose combination tablet, with or without ribavirin
ApprovedWithdrawn 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Cardiac Transplant Disorder
Conditions
Cardiac Transplant Disorder, Hepatitis C
Trial Timeline
Aug 1, 2018 → Jun 30, 2021
NCT ID
NCT03026023About Combindation treatment with Grazoprevir and Elbasvir fixed dose combination tablet, with or without ribavirin
Combindation treatment with Grazoprevir and Elbasvir fixed dose combination tablet, with or without ribavirin is a approved stage product being developed by Merck for Cardiac Transplant Disorder. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT03026023. Target conditions include Cardiac Transplant Disorder, Hepatitis C.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03026023 | Approved | Withdrawn |
Competing Products
20 competing products in Cardiac Transplant Disorder